RENEURON GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.375 GBX | -2.17% |
|
-.--% | -3.57% |
| Apr. 17 | ReNeuron Group Reports CFO Resignation | MT |
| Apr. 17 | ReNeuron CFO steps down to pursue other opportunities | AN |
Presenter SpeechOlav Hellebø (Executives)Good afternoon, everyone. Wonderful to see so many pe...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Companyâs CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
Calendar
2024-07-10
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.57% | 2.4M | |
| +0.76% | 43.84B | |
| +5.58% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.39% | 25.53B | |
| -25.17% | 18.18B | |
| -3.09% | 12.29B | |
| +26.52% | 12.29B | |
| +6.92% | 11.15B |
- Stock Market
- Equities
- RENE Stock
- News ReNeuron Group plc
- Transcript : ReNeuron Group plc, H1 2022 Earnings Call, Nov 30, 2021
